The Food and Drug Administration (FDA) has announced updates to the labeling of all extended-release stimulant medications indicated for attention-deficit/hyperactivity disorder (ADHD) because of a known risk of significant weight loss in children under 6 years of age. Clinically significant weight loss (at least a 10% decrease in the Centers for Disease Control and Prevention weight percentile) was observed in both short- and long-term studies with extended-release stimulants. The revised labeling will apply to extended-release …
Read More